(1) Eligible studies include original research involving human participants (such as randomized controlled trials, cohort studies, case-control studies, cross-sectional studies) or comprehensive reviews (such as systematic reviews and scoping reviews). (2) Studies must be published between January 1, 2019, and December 31, 2024. (3) Only publications in English or Chinese are considered. (4) All included literature must be peer-reviewed, formal publications.

The study population must consist of patients with clinically diagnosed PD, with no restrictions on age, disease stage, or treatment background.

Studies must closely revolve around the theme of “monitoring technologies for Parkinson disease.” Specifically, they should report data or provide in-depth discussion on at least one of the following aspects: (1) technological performance, such as the accuracy, sensitivity, specificity, reliability, or feasibility of the monitoring technology; (2) clinical validation, such as the effectiveness of the technology in real-world or clinical settings, its correlation with clinical assessment outcomes, or its impact on the clinical decision-making process; and (3) implementation challenges, such as barriers, limitations, cost, accessibility, or ethical issues encountered during the practical promotion and application of the technology.

This study does not impose restrictions on the application settings of the technologies (eg, home, community, clinic, hospital) or on geographic or cultural backgrounds, aiming to comprehensively gather relevant evidence from a global perspective.

Wearable sensors, especially devices utilizing IMUs, have markedly improved the objectivity and continuity of home-based monitoring for PD motor symptoms through multisite deployment and functional integration (Multimedia Appendix 3). Wearable systems employ either distributed placement (eg, wrist, ankle, waist) or targeted designs, enabling concurrent monitoring of core motor features such as tremor, bradykinesia, and gait abnormalities, as well as quantitative tracking of motor fluctuations and dyskinesia [9-12]. Multisensor solutions—such as PDMonitor and Kinesia 360—enhance symptom detection sensitivity by simultaneously monitoring the limbs and trunk, while single-device platforms, such as Personal KinetiGraph (PKG) smartwatches and STAT-ON, prioritize efficient identification of specific symptom domains [9-11,13].

Recent innovations in sensor design extend beyond conventional motion signal detection. For instance, smart insoles such as FeetMe Monitor deliver multidimensional analysis of gait and plantar pressure by merging IMU and pressure sensor data [13]. However, clinical implementation of multisensor technologies is impeded by concerns regarding wearability and a tendency toward lower long-term adherence as the number of sensors increases. Small-scale studies report high adherence (13-16 hours/day) with 3 or fewer sensors [14], although this may not generalize beyond motivated populations. Increased sensor burden is linked to discomfort and practical obstacles (eg, difficulty dressing), elevating dropout rates in less controlled and longer-term deployments. Furthermore, older patients frequently report usability challenges, leading to lower acceptance of complex multisensor systems [58].

Beyond initial device costs, the sustainability of mobile PD monitoring technologies poses an economic challenge. A review by the International Parkinson and Movement Disorder Society Task Force on Technology emphasizes the current lack of robust business models to incentivize health care payer reimbursement, coupled with a dearth of cost-effectiveness analyses [59]. Hidden costs such as maintenance, data subscriptions, and clinician interpretation time compound the economic burden and create significant barriers for resource-limited populations and health care systems. This highlights the urgent need for simplified, affordable monitoring solutions.

The clinical translation of emerging sensor modalities (eg, sweat analyzers, smart insoles) is hampered by data standardization challenges: (1) the absence of cross-manufacturer calibration standards impedes direct comparison of metrics such as gait symmetry or plantar pressure across devices (eg, FeetMe vs pressure mats); (2) temporal alignment difficulties in fusing heterogeneous sensor streams (such as synchronizing IMU and biochemical data) complicate reliable multimodal analysis and commonly require sophisticated hardware or software solutions [58].

These advances improve symptom quantification and treatment planning. Bio-integrated remote monitoring platforms with flexible, stretchable electronics are particularly promising for overcoming wearability constraints. By forming comfortable, skin-conformal interfaces, these next-generation systems minimize motion artifacts and enhance patient acceptance, representing a crucial advance for sustained long-term monitoring [60].

The diverse landscape of wearable technologies, as summarized in Table S1 in Multimedia Appendix 3, demonstrates a common pursuit of high objective performance (eg, accuracy and specificity often >0.85 for PDMonitor). However, direct comparison of these metrics across devices is challenging due to pronounced methodological heterogeneity. Studies employed different gold standards (eg, UPDRS items, Abnormal Involuntary Movement Scale, expert diary), patient cohorts (varying disease stages), and outcome definitions (eg, thresholds for symptom detection). For instance, although PKG data led to treatment changes in most visits (71/85, 84%), its symptom detection profile (bradykinesia, 15/30, 50%, and 10/30, 33%, dyskinesia) reflects its specific algorithmic focus and validation context, not necessarily an absolute performance ranking. This heterogeneity indicates that high accuracy figures represent proof of efficacy within specific study frameworks, highlighting potential rather than universal clinical readiness. Key translational gaps, consistent across devices, include the need for standardized validation protocols and real-world cost-effectiveness analyses.

The adoption of computer vision technology combined with algorithms has introduced a powerful approach for remote, quantitative assessment of PD motor symptoms. Applications encompass diverse domains, from analyzing respiratory patterns to evaluating total body movements. Deep learning and pose estimation algorithms (eg, MediaPipe, OpenPose) enable automated measurement of indicators such as finger-tapping amplitude, hand speed, and limb agility via standard cameras or depth sensors. Notable achievements include multicenter validations of OpenPose, which, under controlled assessment protocols, obtained over 80% binary classification accuracy for leg movements and moderate concordance with clinician ratings (ICC 0.74) [15]. ICC over 0.7, while encouraging for research, falls short of the standard required (ie, >0.9) for clinical replacement, limiting these tools to adjunctive roles. Similarly, analyses indicate that computational metrics can be statistically correlated with Movement Disorder Society-UPDRS (MDS-UPDRS) scores (eg, ρ=0.361, P<0.1) [16], yet this magnitude accounts for only about 13% of clinical variance, suggesting that current computer vision approaches have yet to fully capture the spectrum of symptom severity as evaluated clinically. In parallel, novel approaches such as Massachusetts Institute of Technology’s respiratory analysis system leverage long short-term memory models to interpret nocturnal breathing for disease severity prediction, achieving an AUC of 0.89 in their validation cohort, indicating strong discriminative ability in a research context. However, as with all laboratory-derived metrics, its performance in unselected real-world populations remains to be validated [17]. These advances promote objective, contactless evaluation and facilitate home-based monitoring and remote care.

Nonetheless, the deployment of computer vision in uncontrolled home environments faces robustness limitations. The accuracy of skeletal tracking algorithms is sensitive to nonoptimal conditions: subpar lighting, occlusion, and camera angles can diminish performance. Comprehensive reviews confirm that both camera parameters and environmental factors critically affect pose estimation accuracy [61] and that current markerless systems have strict requirements for acquisition environments [62]. Enhancing robustness for home use requires strategies such as data augmentation (simulating varying lighting and backgrounds), expanding training datasets to include multiple scenarios, and employing low-light imaging hardware and algorithms.

Additionally, the use of video-based assessments raises explicit patient privacy concerns. Video data—including facial and bodily motion—constitute biometric identifiers and are protected health information under the Health Insurance Portability and Accountability Act (HIPAA). Compliant systems must employ comprehensive safeguards: technical measures (encryption, anonymization), administrative protocols (business associate agreements and strict access controls), and physical security (secured acquisition and storage devices). For example, deidentifying video data before analysis aligns with HIPAA’s Privacy Rule and is foundational to privacy-preserving clinical practice [63].

The current reliance on standardized laboratory tasks, while facilitating initial validation, restricts ecological validity and scalability. A future priority is capturing spontaneous, real-world motor symptoms in unstructured daily settings, as this represents a critical next step for computer vision to achieve continuous and clinically meaningful PD assessment.

A comparative view of computer vision systems (see Table S2 in Multimedia Appendix 3) reveals a trend toward robust performance in controlled settings (eg, AUCs of 0.85-0.91 for the MIT respiratory system). However, a critical appraisal must consider the validation context. High ICC values (eg, 0.74 for KELVIN) and correlations with UPDRS, although statistically significant, account for only a limited portion of clinical variance and originate from protocols using standardized, scripted movements. This indicates a current limitation in ecological validity—the ability to assess spontaneous symptoms in naturalistic environments. The performance decline observed in some applications when moving from controlled to uncontrolled settings further illustrates this “bench-to-bedside” gap. For example, one study reported that voice analysis accuracy decreased from 92% in laboratory conditions to 71% in home environments—a 21-percentage-point decline that highlights the vulnerability of laboratory-trained models to real-world environmental variability (background noise, inconsistent recording conditions). This finding underscores that high accuracy in controlled studies does not guarantee clinical utility in home settings. Therefore, the metrics in Table S2 in Multimedia Appendix 3 primarily serve as benchmarks for technical validation under optimal conditions. The next developmental leap requires demonstrating that these systems can maintain accuracy, robustness to environmental variables (eg, lighting, occlusion), and user-friendliness during continuous, unstructured home monitoring, which remains a significant translational challenge.

Sleep disturbances are widely prevalent in PD. Monitoring technologies range from single-motion recorders to multimodal systems. Flexible electrode arrays combining electroencephalogram, electrooculogram, and electromyography signals have achieved strong agreement with the gold-standard laboratory video polysomnography, demonstrating a sensitivity of 76.8% for detecting muscle atonia during rapid eye movement sleep [35]. Wrist-worn actigraphy devices, using triaxial accelerometry, have delivered up to 92.9% screening accuracy for rapid eye movement sleep behavior disorder in laboratory settings; during 2-week home monitoring, models achieved 100% accuracy within specific PD subgroups and 94.4% accuracy among controls with insomnia [37]. However, the generalizability of these findings requires substantiation through larger, multicenter cohorts.

The Kronowise 3.0 device, integrating wrist temperature, acceleration, and environmental light exposure, reveals no significant discrepancies in core sleep parameters when compared with video polysomnography [30]. Multimodal signal technologies enhance both accuracy and convenience, particularly in home environments, thereby supporting early detection and screening of sleep disturbances in PD.

Environmental factors also significantly influence sleep in PD, as verified by interventional studies. Insufficient daylight exposure and excessive nocturnal light have a direct negative impact on sleep efficiency among patients [38]. Concurrently, a decreased frequency of nighttime bed-turning—confirmed by waist-worn accelerometers—correlates with worsening motor symptoms [64]. Integrated smartphone and wearable trackers have identified a bidirectional causal link between poor sleep quality and subsequent daytime anxiety levels [31], and sleep headbands demonstrate that longer supine sleep periods correspond with heightened dyskinesia severity [34]. Collectively, these technologies provide valuable insights for clinical management.

Despite these advancements, monitoring performance often declines when conducted in real-life home environments due to environmental noise, variability in sensor placement, and inconsistent user compliance. This indicates that findings from controlled settings may not readily generalize.

In addition, systems based on wearable devices have limited sensitivity in detecting lighter sleep stages, particularly transitional states such as N1 sleep. Most reported performance indicators are derived from pilot groups with specific inclusion criteria and should therefore be interpreted with caution. Overall, the existing evidence supports the feasibility of intelligent sleep monitoring in the management of PD, but its reliability and generalizability in long-term, free-living environments still require further confirmation.

Autonomic nervous system dysfunction in PD affects cardiovascular, gastrointestinal, and thermoregulatory domains. Intelligent assessment technologies directly capture physiological signals (Table S4 in Multimedia Appendix 3).

In cardiovascular monitoring, chest straps (eg, POLAR H10) and wristwatches (eg, POLAR V800) facilitate 24-hour heart rate interval recording. Heart rate variability metrics such as SD of normal-to-normal intervals and coefficient of variation of R-R intervals demonstrate high diagnostic utility (AUC 0.90) and can be detected before overt clinical symptoms [40]. Wireless blood pressure monitors offer simultaneous measurement of blood pressure, heart rate, oxygen saturation, and body temperature, autonomously detecting and signaling episodes of orthostatic hypotension with intelligent alerts and support for teleconsultations [43].

In auditory symptom detection, professional and smartphone microphones have demonstrated impressive accuracy rates of 94.55% and 92.94%, respectively, for PD voice analysis [41]. Mobile voice analytics systems also show efficacy in supporting symptom identification in controlled settings [42].

Multimodal intelligence is key for early detection. Combined biometric analysis using smartphone cameras and voice signals from laboratory-controlled samples allows joint assessment of facial expression and voice, aiding early-stage PD diagnosis (AUC 0.85); however, broader clinical validation is needed. Smartwatches can monitor swallowing dysfunction by detecting delayed hand-to-mouth movements [45], while PKG recorders link bradykinesia to constipation, providing quantifiable gastrointestinal dysfunction metrics [36].

Although wearable systems can correlate sleep activity with autonomic function scores, personalized prediction remains challenging [33]. Interpretation of metrics such as heart rate variability is complicated by inter- and intraindividual variability, particularly during longitudinal monitoring. Addressing these challenges requires the establishment of personalized reference baselines and advanced analytical techniques (eg, dynamic baseline models, covariate adjustments). Improving accuracy will require multimodal devices capable of integrating photoplethysmography, electrodermal activity, and movement data.

Most nonmotor symptom monitoring studies remain at the pilot or experimental validation stage, with limited evidence from long-term deployment in routine clinical practice. Importantly, reported performance metrics vary considerably across studies due to differences in sensor types, monitoring duration, sample size, and validation settings; therefore, direct quantitative comparisons between studies are not appropriate. This heterogeneity constrains the generalizability of current findings and should be carefully considered when interpreting reported performance.

Overall, intelligent identification of nonmotor symptoms in PD remains an evolving field. Although existing studies demonstrate technical feasibility across multiple symptom domains, most systems have been validated in small-scale or short-term settings. Future research should prioritize longitudinal monitoring, multimodal integration, and clinically interpretable outputs to enhance translational value.

Nonmotor monitoring demonstrates technical feasibility but limited clinical utility. Conceptually, sleep data could guide clinical decisions: rapid eye movement sleep behavior disorder detection might prompt melatonin or dopaminergic timing adjustments [35,37], sleep efficiency metrics could inform light exposure therapy [38], and reduced mobility might trigger fall prevention counseling [64]. Similarly, autonomic data could guide cardiovascular risk management [40] or orthostatic hypotension interventions [43].

However, these pathways remain largely theoretical. No study has demonstrated that acting on algorithm-detected sleep or autonomic abnormalities improves patient outcomes, reduces hospitalizations, or enables superior medication optimization compared with standard care. Key barriers include the inability to separate mixed symptom etiologies (eg, sleep fragmentation due to hypokinesia versus depression), the lack of validated thresholds linking specific values to specific actions, and the absence of prospective trials with hard clinical end points. At present, nonmotor monitoring primarily documents physiological patterns without supporting evidence for evidence-based therapeutic decisions.

These clinical limitations reflect deeper structural barriers. Nonmotor monitoring lags behind motor technologies in regulatory clearance and outcome trials [9,10,12]. Four structural barriers help explain this gap.

These fundamental barriers require new sensors, personalized baselines, and outcome trials—not just improved algorithms.

The accuracy, AUC, and ICC values reported in this section represent technical validation results rather than evidence of clinical efficacy. Three limitations apply: studies used different methods and populations, preventing direct comparison; performance often declines in real-world use [35,41]; and no study has demonstrated that these measures improve patient outcomes. These figures illustrate technological potential but do not support conclusions about clinical readiness or comparative effectiveness.

Single-modality approaches use one type of data or sensor to build models (Table S5 in Multimedia Appendix 3). Convolutional neural networks (CNNs), frequently combined with other algorithms, are prominent for extracting spatial features from movement data in PD [18]. San-Segundo et al [19] reported laboratory-based use of CNNs for tremor percentage estimation, achieving error rates below 5%. While this indicates strong performance under controlled conditions, laboratory-optimized algorithms often experience accuracy declines when deployed in uncontrolled home environments due to signal variability. Additionally, lightweight models tailored for wearable sensors are advancing. Borzì et al [20] combined simple thresholding with CNNs for home-based freezing-of-gait detection, achieving 96% sensitivity. However, sensitivity alone does not capture the full picture; specificity and real-time performance in varied daily contexts are equally critical for clinical utility.

Beyond classic motion sensors, modalities including eye tracking, plantar pressure, and voice analysis (eg, studies by Amato, Chudzik, and Tsakanikas [21,22,65]) are broadening the scope of single-modality PD feature extraction.

Despite their utility, single-modal techniques often yield lower accuracy in real-world, nonlaboratory conditions due to the variability of daily activities and the heterogeneity of PD symptoms. As demonstrated by Sigcha et al [18], consumer smartwatches and deep learning improve early-stage PD monitoring; however, additional validation is essential for advanced-stage disease with more pronounced symptoms. Error propagation remains a concern (eg, rest-period misclassification), requiring more parameters and increasing model complexity. Overall, single-modal approaches have limited predictive validity for the total UPDRS score, as they mainly quantify motor function [66]. For nonmotor symptoms such as sleep disturbances, precision remains to be optimized [23].

Multimodal intelligent monitoring integrates multiple heterogeneous data modes to achieve a comprehensive, continuous, and accurate assessment of PD. Multimodal integration relies on hierarchical data fusion, and common strategies mainly include feature-level fusion and decision-level fusion (see Table S6 in Multimedia Appendix 3).

In feature-level fusion, the research constructs a unified high-dimensional feature representation by integrating the original or intermediate features from different modes. For example, by simultaneously analyzing the patient’s voice signal and facial video features and using machine learning algorithms for modeling, the PD detection accuracy can reach as high as 83% [24]. In addition, to more comprehensively assess fall risk in a free-living environment, gait data and video eye-tracking data are combined. By using the fine-tuned YOLOv8 target detection algorithm to identify objects (such as obstacles and stairs) and potential hazards in the environment, and combining this with an overlap detection algorithm to analyze the intersection of the patient’s fixation point, walking path, and hazards, the approach can provide key environmental context information for gait fluctuations and enhance the perception of fall risk [25].

At the same time, techniques such as multigranularity computation, rough set theory, and composite algorithms strengthen robustness. For instance, one study reported 98.9% accuracy for gait activity recognition using a CNN-recurrent neural network ensemble [67]. Although this suggests excellent performance on their specific dataset, such high values often reflect optimization on curated, task-specific data and may not generalize to the heterogeneity of free-living conditions.

In decision-level fusion, models first classify or regress data from each modality independently and then integrate the outputs from individual models. For example, constructing a digital health technology composite score by combining sensor features from multiple active and passive tests can provide a more robust assessment of overall PD severity. In addition, machine learning models have been used to predict MDS-UPDRS total scores or distinguish “on/off” states by fusing multisource features, enabling multidimensional information integration and final decision-making. These methods demonstrate good reliability and validity in early-stage PD populations and provide a digital basis for tracking disease progression [27].

Cross-modal fusion faces many technical challenges, especially feature synchronization. Consistency across data streams is vital to suppress false classifications. Diverse sampling rates and structures necessitate complex temporal alignment. In addition, domain adaptation is indispensable to counteract device and environment biases, and data augmentation strategies help offset small sample limitations (eg, Shin et al’s [28] variable window shifting). These methods collectively help maintain stable performance across limited and heterogeneous datasets.

Federated learning—a distributed model training approach without raw data sharing—offers promise for cross-center collaboration in PD monitoring by enhancing privacy and scalability (see Table S7 in Multimedia Appendix 3). The study emphasizes that clinical data for PD encompass multimodal information on both motor and nonmotor features, such as images and wearable sensor data, providing abundant resources for federated learning applications [68]. The Diversity-Aware Activity Recognition framework, for example, clusters users by gait, activity, and social factors using K-means, enabling personalized model initialization and feature extraction [29]. This approach improves recognition of “cold-start” new users by 5.5%, and diversity-aware models demonstrate strong generalization across multiple activity tasks [29].

Key challenges include significant data distribution differences across users or devices, which affect the model’s generalization ability. The introduction of noise in differential privacy mechanisms may reduce data utility; therefore, it is necessary to further optimize the privacy budget and noise mechanisms to balance privacy and utility [29]. The deployment of federated learning frameworks on mobile devices is also limited by computing resources and energy consumption [29]. In addition, medical data are mostly unstructured and lack unified annotation, which affects the quality of model training, and the design and implementation of the entire system must comply with data privacy regulations such as the General Data Protection Regulation and HIPAA [68].

Future directions include the use of federated learning to promote multimodal intelligent monitoring of PD. First, promote multimodal feature fusion by integrating wearable sensors, voice, and image data [69]. Second, develop personalized and adaptive models and use meta-learning, transfer learning, and other technologies to help models better adapt to heterogeneous data [29]. Third, promote lightweight and edge-computing deployment of models to adapt to the resource constraints of mobile devices and enable real-time monitoring and feedback [29]. Fourth, carry out cross-center clinical verification and evaluate the effectiveness and safety of the federated learning system in real clinical scenarios through multiagency collaboration [68]. Continued advancements in multimodal symptom monitoring will be achieved by optimizing feature extraction and fusion, combined with deeper integration of federated learning for secure, efficient data sharing and model training. This convergence will drive systems toward greater intelligence, personalization, and clinical applicability, underpinning precision diagnosis and management of PD.

The swift expansion of telemedicine has created ample opportunities for deploying intelligent monitoring technology in PD [43,70,71]. Since the advent of COVID-19, remote neurology consultations have increased by 17%. Notably, 98% of surveyed deep brain stimulation patients express a strong interest in remote management [46], representing a major catalyst for remote monitoring platforms. Accompanying these trends, acceptance rates for wearable and environmental sensors reach 87% and 100%, respectively [14], setting a robust social foundation for clinical translation.

The technical foundations have simultaneously matured: digital monitoring of PD symptoms demonstrates notable progress (PDMonitor tremor detection reports 99% concordance with MDS-UPDRS-III [10]), and cross-modal algorithmic optimization elevates fall risk prediction to 83% accuracy [13]. Together, these improvements unite hardware and software for reliable remote monitoring platforms.

Remote monitoring platforms now span the entire continuum of PD management. Health care interaction–optimized platforms facilitate secure, efficient communication for individualized care (eg, MoveONParkinson achieves a System Usability Scale score of 79.50, 95% CI 73.70-85.30 [47]; RM App attains 85.5%, 172/201, adherence among deep brain stimulation patients [48]). Symptom-oriented platforms provide real-time physical symptom tracking and detailed assessment (QDG-Care and iHandU focus on tremor quantification [49,50], and PDxOne on gait analysis [51]). Comprehensive platforms, such as My Parkinsoncoach, integrate wearables and smartphones to collect data, deliver feedback, reduce outpatient visits by 29%, and enhance patient empowerment; solutions such as uMotif, Fox Wearable Companion, and PD Dr optimize medication tracking [72]. Nonetheless, integrated remote monitoring platforms encompassing both motor and nonmotor symptoms are still evolving—MoveONParkinson, for example, is limited to conversational interactions, while PDxOne focuses solely on gait. Such segmentation hinders holistic disease management and longitudinal care decisions.

Meanwhile, innovative rehabilitation solutions are broadening the implementation ecosystem for PD. Platforms such as “Shou Pa” incorporate Tai Chi to boost adherence, and initiatives such as ACTIVA, i-PROGNOSIS, and Rhythm Workers use virtual games for intensive motor training [53], illustrating a growing diversity of technological approaches.

While these platforms demonstrate technical excellence in their respective domains—including motor assessment, decision support, and treatment optimization—they are primarily focused on single functions or specific points in the care pathway. For example, SMaRT-PD provides a rule-based clinical decision support system that integrates multimodal data (wearable sensors, patient-reported outcomes, and care records) to generate personalized, symptom-specific management recommendations [54]. QDG-Care delivers validated quantitative metrics of motor symptoms through a fully integrated connected platform, with components spanning a dedicated digitography device, patient app, cloud-based algorithm service, provider dashboard, and electronic health record integration [49].

Identifying recurring challenges and themes in existing platforms informs the development of the Care-Platform Transformation in PD (CPT-PD) framework, which synthesizes key ingredients for effective PD monitoring (Figure 2). This is a reference model that draws on retrospective lessons rather than offering prescriptive advice and is intended to support the design of holistic, integrated remote monitoring platforms (Textbox 1).

The synthesized framework (Textbox 1) offers a structured tool for analyzing platform strengths and weaknesses and a road map for overcoming fragmentation and enhancing clinical integration.

To validate the clinical applicability of this framework, we present the “My Parkinsoncoach” platform, which has successfully reduced outpatient burden in PD. This case example demonstrates how it organically integrates the longitudinal pathway, horizontal architecture, and collaborative ecosystem of the CPT-PD framework [52].

The platform’s development clearly follows the longitudinal, clinically driven pathway: it began by identifying the unsustainable burden of frequent outpatient visits; invented an integrated solution comprising periodic electronic questionnaires, visual symptom-domain scoring, clinician-patient communication, and educational modules; and implemented the system through a prospective cohort study that verified a 29% reduction in outpatient visits and a 39% decrease in health care costs. This structured development process is a key reason for the platform’s success.

We now explain the platform through the horizontal 4-layer architecture: its presentation layer provides role-specific, user-friendly interfaces for patients and clinicians; the business logic layer automatically converts questionnaire responses into trend scores across 15 symptom domains (eg, motor symptoms, activities of daily living) and implements a clinical response protocol whereby specialized nurses handle initial alerts and neurologists provide backup; the data access layer securely manages these multimodal patient-reported data; and the entire system operates on a stable infrastructure layer (network connectivity).

Within this architecture, the 5 key collaborative elements work in synergy to sustain stable platform operation: patients submit data via the mobile interface; specialized nurses and neurologists interpret the data and intervene based on prompts from the business logic layer; platform operators ensure system stability; the platform itself serves as the integrated functional carrier; and the broader community (eg, family caregivers)—although not highlighted in the original study—represents a natural extension for scaling the model into home-based care.

Applying this case to the CPT-PD framework demonstrates its ability to deconstruct the design logic and core components of a successful platform. At the same time, it reveals areas for framework refinement—notably, the integration of the “community” element remains underdeveloped. This insight points the way toward future optimization of both the “My Parkinsoncoach” platform and the CPT-PD framework itself.

Despite progress, only a minority of monitoring devices have transitioned into remote monitoring platforms. This translational bottleneck fundamentally stems from a mismatch between reported performance and clinical readiness. While many studies demonstrate promising results in controlled pilot settings (Technology Readiness Level ~4-5), only a few progress to robust validation in heterogeneous, real-world clinical environments (Technology Readiness Level 7-8), creating a “readiness gap” that hinders broad adoption [73]. This gap is compounded by several persistent bottlenecks: